Exploring the Frontiers of Atopic Dermatitis: From Pathogenesis to Therapeutic Strategies
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions. In recent years, with the deepening understanding of AD pathogenesis, scientists have discovered that various cytokines and signaling pathways play pivotal roles in the disease process, providing a theoretical basis for the development of novel therapeutic targets.
- Recent Advances
Exploring the Frontiers of Atopic Dermatitis: From Pathogenesis to Therapeutic Strategies
Atopic dermatitis (AD) is a common chronic inflammatory skin disease characterized by intense pruritus and recurrent eczematous lesions. In recent years, with the deepening understanding of AD pathogenesis, scientists have discovered that various cytokines and signaling pathways play pivotal roles in the disease process, providing a theoretical basis for the development of novel therapeutic targets.
Promising Target Proteins Pioneering New Treatment Directions
IL-4Rα is the common receptor for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines that play a central role in the inflammatory response of AD. Dupilumab (Dupixent), the first biologic agent targeting IL-4Rα, has significantly improved symptoms in AD patients by blocking the signal transduction of IL-4 and IL-13.
OX40 Ligand (OX40L) is another highly anticipated target. The binding of OX40 to its ligand activates T cells and promotes inflammatory responses. Studies have shown that blocking the OX40/OX40L signaling pathway can effectively alleviate AD symptoms. For instance, Amlitelimab, a monoclonal antibody targeting OX40, has demonstrated favorable efficacy in clinical trials.
IL-31 plays a critical role in the pruritus experienced by AD patients. Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, has been approved for the treatment of moderate-to-severe AD patients.
Youai Target Proteins: A Reliable Partner for Research and Clinical Applications
Youai is committed to developing high-quality target proteins to provide robust support for the research and treatment of atopic dermatitis. Youai's target proteins undergo rigorous quality control, ensuring high purity and biological activity, making them suitable for various experiments such as antibody screening and cell activity assays.
Future Outlook
As the exploration of AD pathogenesis continues, more potential therapeutic targets will be uncovered. Youai remains committed to staying at the forefront of scientific research, continuously optimizing our products, and assisting scientists in developing more effective treatment regimens, bringing new hope to AD patients.
Partial List of Available Products:
|
Catalog Number |
Product |
|
IL-4R alpha/CD124 His Tag Protein, Human |
|
|
IL-4 Protein, Human |
|
|
UA010778 |
OX40 Ligand/TNFSF4 His Tag Protein, Cynomolgus |
|
UA040227 |
IL-31 Protein, Human |
|
IL-31RA Fc Chimera Protein, Mouse |
|
|
TSLP Protein, Human |
|
|
Fc epsilon RI α Fc Chimera Protein, Human |
|
|
IL-17F Protein, Human |
|
|
BTLA Fc Chimera Protein, Human |
|
|
IL-5 Protein, Human |
|
|
IL-18 Protein, Huma |
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 